ReviewCancer gene therapy2015
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.
Review in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.Discover oncology · 2025Review
- Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.AAPS PharmSciTech · 2024Review
- Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.Frontiers in immunology · 2024Review
- High-efficiency targeted transgene integration via primed micro-homologues.Cell discovery · 2023Article
- Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.Current oncology (Toronto, Ont.) · 2023Review
- CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges.Biochemical genetics · 2022Review
- Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.Molecular cancer · 2022Review
- CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer.Advanced pharmaceutical bulletin · 2022Review
- CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.Cancer gene therapy · 2021Review
- Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications.Molecular biotechnology · 2021Review
- Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.Clinical & translational immunology · 2021Review
- Illuminating lncRNA Function Through Target Prediction.Methods in molecular biology (Clifton, N.J.) · 2021Article
- CRISPR: a journey of gene-editing based medicine.Genes & genomics · 2020Review
- Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.Molecular biology reports · 2020Article
- Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- NCAPG Is a Promising Therapeutic Target Across Different Tumor Types.Frontiers in pharmacology · 2020Article
- Article
- Blossom of CRISPR technologies and applications in disease treatment.Synthetic and systems biotechnology · 2018Review
- Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors.Molecular therapy. Nucleic acids · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although varied drugs and therapies have been developed for lung cancer treatment, in the past 5 years overall survival rates have not improved much. It has also been reported that lung cancer is diagnosed in most of the patients when it is already in the advanced stages with heterogeneous tumors where single therapy is mostly ineffective. A combination of therapies are being administered and specific genes in specific tissues are targeted while protecting normal cell, but most of the therapies face drawbacks for the development of resistance against them and tumor progression. Therefore, therapeutic implications for various therapies need to be complemented by divergent strategies. This review frames utilization of CRISPR/Cas9 for molecular targeted gene therapy leading to long-term repression and activation or inhibition of molecular targets linked to lung cancer, avoiding the cycles of therapy.
Indexed as
Identifiers
26494554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.